Alnylam Pharmaceuticals is the world's leading RNA interference therapeutics company and one of the world's leading biotechnology companies.
Alnylam Pharmaceuticals is the pioneer and global leader in RNA interference therapeutics, having translated the Nobel Prize-winning RNAi mechanism into five approved commercial therapies. Headquartered in Cambridge, Massachusetts, the company generated approximately $2.5 billion in 2025 revenue with strong growth driven by inclisiran (Leqvio) for cardiovascular disease and vutrisiran (Amvuttra) for hereditary transthyretin amyloidosis. Alnylam's GalNAc delivery technology enables subcutaneous administration of RNAi therapeutics with dosing as infrequent as once or twice per year — a significant convenience advantage over daily oral medications. The company's pipeline extends RNAi across metabolic, cardiovascular, neurological, and hepatic disease.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Financial performance 2023-2025
• SWOT analysis
• Technological know-how and platform capabilities
• Latest products, pipeline, and R&D programs
• M&A and partnership activity 2023-2025
• Marketing tactics and commercial strategy
• Organization and management
Table of Contents
1. Executive Summary
2. Company Overview
3. Strategic Directions
4. Financial Performance
5. SWOT Analysis
6. Technological Know-How and Key Products
7. M&A and Partnerships
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Alnylam Pharmaceuticals — Key Financial Metrics 2023-2025
Table 2. Alnylam Pharmaceuticals — Revenue by Product 2023-2025
Table 3. Alnylam Pharmaceuticals — Revenue by Geography 2023-2025
Table 4. Alnylam Pharmaceuticals — R&D Investment 2023-2025
Table 5. Alnylam Pharmaceuticals — SWOT Analysis
Table 6. Alnylam Pharmaceuticals — Key Products and Pipeline 2025
Table 7. Alnylam Pharmaceuticals — M&A Activity 2020-2025
Table 8. Alnylam Pharmaceuticals — Key Management 2025
Table 9. Alnylam Pharmaceuticals — Strategic Priorities 2025-2030
